Persistent disabling breathlessness in chronic obstructive pulmonary disease
2016 (English)In: The International Journal of Chronic Obstructive Pulmonary Disease, ISSN 1176-9106, E-ISSN 1178-2005, Vol. 11, 2805-2812 p.Article in journal (Refereed) Published
Objective: To determine the prevalence, change in breathlessness status over time, and risk factors for disabling and persistent disabling breathlessness in relation to treatments in chronic obstructive pulmonary disease (COPD).
Materials and methods: Longitudinal analysis of data from the Swedish National Register of COPD with breathlessness measured using modified Medical Research Council (mMRC) scores at two subsequent visits. Prevalence of disabling breathlessness (mMRC. 2 at baseline) and persistent disabling breathlessness (disabling breathlessness at baseline and follow-up) was investigated in relation to COPD treatment. Risk factors for disabling breathlessness, change from non-disabling to disabling breathlessness, and persistent disabling breathlessness were analyzed using multiple logistic regression.
Results: A total of 1,689 patients were included in the study with a median follow-up of 12 months (interquartile range: 4 months). Prevalence of disabling breathlessness was 54% at baseline. Persistent disabling breathlessness was present in 43% of patients despite treatment and in 74% of patients despite combined inhaled triple therapy and physiotherapy. Risk factors for disabling breathlessness or change to disabling breathlessness were higher age, lower lung function, frequent exacerbations, obesity, heart failure, depression, and hypoxic respiratory failure (all P < 0.05). Persistent disabling breathlessness was associated with lower lung function and ischemic heart disease (all P < 0.05).
Conclusion: Disabling breathlessness is common in COPD despite treatment, which calls for improved symptomatic treatments and consideration of factors influencing disabling breathlessness. Factors influencing disabling breathlessness should be considered for COPD management.
Place, publisher, year, edition, pages
Albany, Auckland, New Zealand: Dove Medical Press , 2016. Vol. 11, 2805-2812 p.
COPD, breathlessness, dyspnea, longitudinal analysis, treatment, risk factors
Respiratory Medicine and Allergy
Research subject Pulmonary Medicine
IdentifiersURN: urn:nbn:se:oru:diva-53708DOI: 10.2147/COPD.S119992ISI: 000387436400001PubMedID: 27877034ScopusID: 2-s2.0-84995662757OAI: oai:DiVA.org:oru-53708DiVA: diva2:1051109
Region Örebro County - ALF (Avtal om Läkarutbildning och Forskning)2016-12-012016-12-012016-12-01Bibliographically approved